Tempus AI Beats Estimates, Raises Revenue Forecast

The genomic testing and data company reported third-quarter 2026 revenue of $411.5 million and lifted its full-year outlook.

Updated on Nov. 2, 2026 in Healthcare

Matte gray genomic sequencing instruments in a row on a clean white laboratory bench under even daylight. — Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year, and raised its full-year revenue forecast to $1.60 billion to $1.61 billion. AI Illustration. Upload story photo >

Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year and above analyst estimates of $409 million, and raised its full-year 2026 revenue forecast to $1.60 billion to $1.61 billion. Shares of the company climbed almost 10% on Monday, November 2.

Why it matters

The results show growth across both of the company's main business lines, with diagnostics and data-driven applications both expanding. The raised forecast and expanded data licensing activity point to continued demand for the company's genomic and clinical data products.

Diagnostics revenue rose 20% to $303.5 million and Data & Applications revenue grew 33% to $108.1 million, while adjusted EBITDA reached $25.6 million. The company now expects adjusted EBITDA of approximately $65 million for 2026.

The players

Tempus AI

A Chicago-based technology company that combines genomic sequencing, clinical data and artificial intelligence to support precision medicine, particularly in oncology.

Nasdaq

The U.S. stock exchange where Tempus AI's shares are traded.

The details

Tempus AI's data licensing bookings exceeded $550 million year to date, including agreements with Bristol Myers Squibb valued at up to $137.5 million and $55 million. The company also said its acquisition of Personalis has cleared regulatory review and plans to expand its research platform to 100,000 whole genomes.

Q3 2026: Tempus AI reports third-quarter revenue and adjusted earnings.
Monday, November 2, 2026: Shares climb almost 10% following the earnings report.
Full-year 2026: Company raises its revenue forecast to $1.60 billion to $1.61 billion.

Healthcare Landscape

Tempus AI's oncology unit growth accelerated to 32%, reflecting the continued uptake of molecular profiling in cancer care. The company's data licensing deals with pharmaceutical partners show that clinical and genomic datasets are becoming a revenue stream alongside testing.

Expanded genomic testing and data platforms could affect how oncology patients receive molecular profiling and treatment selection over time. Changes in test availability and pricing would depend on payer coverage decisions not described in the company's results.

The takeaway

Strong growth across diagnostics and data licensing suggests that genomic and clinical data businesses are gaining commercial traction. Readers following the sector can watch whether the raised forecast holds through the fourth quarter.